Ahead of US Biosimilar Competition for Humira, FDA to Give AbbVie's Upadacitinib Priority Review - The Center for Biosimilars

Ahead of US Biosimilar Competition for Humira, FDA to Give AbbVie's Upadacitinib Priority Review  The Center for Biosimilars

AbbVie has announced that the FDA has accepted for priority review its New Drug Application for upadacitinib for the treatment of rheumatoid arthritis (RA).



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases